RTSL — Rapid Therapeutic Science Laboratories Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.06m
- $3.50m
Annual cashflow statement for Rapid Therapeutic Science Laboratories, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 March 31st | 2019 March 31st | 2020 March 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.55 | -0.349 | -0.625 | -2.87 | -1.79 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 2.38 | 0.043 | 0.179 | 0.557 | 0.419 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.029 | 0.199 | 0.218 | 0.067 | 0.2 |
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -0.13 | -0.107 | -0.191 | -2.21 | -1.15 |
| Capital Expenditures | -0.039 | 0 | -0.155 | -0.293 | -0.039 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | -0.039 | 0 | -0.155 | -0.293 | -0.039 |
| Financing Cash Flow Items | — | — | — | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.173 | 0.096 | 0.48 | 2.19 | 0.998 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.005 | -0.011 | 0.135 | -0.307 | -0.192 |